Cell line · CVCL_0439
Papers32
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 32
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| An inertial-based spiral device for separating rare tumor cells from liquid biopsies. | Bioeng Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Prognostic characteristics of disulfidptosis-related genes across cancers and their potential implications in osteosarcoma. | Sci Prog | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor Extracellular Vesicles lncOSLMT Drives Lung Inflammatory Premetastatic Niche Formation in Osteosarcoma via m6A-Dependent hnRNPA2B1/COX-2 Axis. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MAT2A enhances PARN transcription via SRF to accelerate glycolysis and drive malignant progression in osteosarcoma. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Vascular Niche Facilitates Acquired Drug Resistance to c-Met Inhibitor in Originally Sensitive Osteosarcoma Cells. | Cancers (Basel) | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Effects of osteoblast-derived extracellular vesicles on aggressiveness, redox status and mitochondrial bioenergetics of MNNG/HOS osteosarcoma cells. | Front Oncol | 2022 | Its Methods give the RRID and name the line | PubMed | |
| METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma. | EBioMedicine | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Podoplanin for the Treatment of Osteosarcoma. | Clin Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. | Nat Med | 2018 | Cellosaurus cites it | PubMed | |
| Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. | Cancer Cell | 2017 | Cellosaurus cites it | PubMed | |
| Characterization of the metastatic phenotype of a panel of established osteosarcoma cells. | Oncotarget | 2015 | Cellosaurus cites it | PubMed | |
| Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. | Pediatr Blood Cancer | 2014 | Cellosaurus cites it | PubMed | |
| Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. | PLoS One | 2012 | Cellosaurus cites it | PubMed | |
| Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. | Lab Invest | 2011 | Cellosaurus cites it | PubMed | |
| Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. | Genes Chromosomes Cancer | 2010 | Cellosaurus cites it | PubMed | |
| Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping. | Cancer Genet Cytogenet | 2003 | Cellosaurus cites it | PubMed | |
| Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype? | Bone | 1994 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0439/papers